A traditional Chinese medicine therapy for coronary heart disease after percutaneous coronary intervention: a meta-analysis of randomized, double-blind, placebo-controlled trials

Abstract

Huoxue Huayu therapy (HXHY) has been widely used to treat cardiovascular diseases in traditional Chinese medicine (TCM), such as hypertension, and coronary heart disease (CHD). This study describes a meta-analysis of a series of prospective randomized, double-blind, placebo-controlled trials conducted to evaluate the effect of HXHY on patients with CHD after percutaneous coronary intervention (PCI).The Cochrane Library, PubMed, EMBASE, the China National Knowledge Infrastructure (CNKI), the Chinese Biomedical Literature database and the Wanfang database were searched up until June 2018. A series of randomized controlled clinical trials were included and the subjects were patients with CHD who had undergone PCI. The experimental group was treated with HXHY therapy, and the control group was treated with placebo; meanwhile, all the patients accepted conventional Western medicine. Review Manager 5.3 software was used for the statistical analysis. Ten trials were included in the final study. The overall risk of bias assessment was low. HXHY had a greater beneficial effect on reducing the in-stent restenosis (ISR) rate (RR=0.57, 95% CI [0.40, 0.80], P=0.001) and the degree of restenosis (MD=-8.89, 95% CI [-10.62, -7.17], P<0.00001) compared with Placebo. Moreover, HXHY was determined to be more effective in improving Seattle Angina Questionnaires (SAQ) and the revascularization rate (RR=0.54, 95% CI [0.32, 0.90], P=0.02) compared with Placebo, whereas the rate of death and MI of patients treated with HXHY were no different from those treated with the placebo (P>0.05). Therefore, HXHY is an effective and safe therapy for CHD 1# These authors contributed equally to this work.

Traditional Chinese medicine for ischemic heart disease: clinical manifestations and objective indicators

“…Considering almost every RCT was conducted on the basis of conventional treatment in both TCM group and control group, it is safe to say that TCM can improve clinical e cacy as complementary to western medicine. The improvement of clinical e cacy was coincided with previous reports [25][26][27][28][29][30] .…”

Advances in Research on the circRNA‐miRNA‐mRNA Network in Coronary Heart Disease Treated with Traditional Chinese Medicine

“…HXHY had a greater beneficial effect on reducing the instent restenosis (ISR) rate and the degree of restenosis, improving Seattle Angina Questionnaire (SAQ) scores and increasing the revascularization rate compared with placebo. However, the rate of death and myocardial infarction (MI) of patients treated with HXHY was no different from that of those treated with placebo (P > 0.05) [13].…”

Pharmacological Network Reveals the Active Mechanism of Qi‐Replenishing, Spleen‐Strengthening, Phlegm‐Dispelling, and Blood‐Nourishing Fufang on Coronary Heart Disease

“…Studies have reported the roles of TCM. For example, based on a blinded randomized controlled trial, Chen et al showed that Huoxue Huayu therapy is an effective and safe therapy for patients with CHD after percutaneous coronary intervention; it works by decreasing the degree of restenosis and improving the revascularization rate [ 8 ]. Liu et al suggested that Radix Salvia miltiorrhiza compounds could decrease the risk of CHD by improving the biochemical indices (reducing the levels of triglycerides, cholesterol, and lipids, while increasing the levels of apolipoprotein A/B/E and total bilirubin) of patients with CHD [ 9 ].…”